beta-catenin inhibitor FOG-001

A conformationally stabilized alpha-helical polypeptide and direct inhibitor of the oncogenic driver beta-catenin, with potential immunomodulating and antineoplastic activities. Upon administration, beta-catenin inhibitor FOG-001 penetrates into the cell where it targets and binds to beta-catenin, thereby preventing the interaction of beta-catenin with the transcriptional factor T-cell factor (TCF). This disrupts beta-catenin-dependent oncogenic signaling and prevents the transcription of Wnt target genes that regulate the proliferation, migration, invasion, and the metastatic potential of tumor cells, as well as genes regulating the immunosuppression of the tumor microenvironment (TME). Dysregulation of the Wnt/beta-catenin signaling pathway is found in a variety of tumors and drives oncogenesis.